Molecule profile · Module 7
Thymosin alpha-1 — evidence and research limits
This label describes the research context of this profile, not a product-by-product approval determination. It does not mean every use of the molecule lacks approval. Read the existing evidence details and regulatory context for the specific preparation, indication and jurisdiction; no new approval is inferred.
MOLECULE PROFILE
- Evidence summary
- Investigational — profile context
- Historical hepatitis studies and the TESTS sepsis trial concern different populations and outcomes. TESTS did not demonstrate the primary mortality reduction; its published correction must be read with the original article. Favorable immune markers cannot be reclassified as a demonstrated survival benefit. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
Thymosin alpha-1 has been investigated as an immunomodulatory peptide in specific disease settings. Immune signaling is a regulated network rather than a single defense switch. A favorable biomarker response cannot stand in for improved survival, and evidence from one infection or population does not define a general immune-enhancement indication.
What the evidence supports
Historical hepatitis studies and the TESTS sepsis trial concern different populations and outcomes. TESTS did not demonstrate the primary mortality reduction; its published correction must be read with the original article. Favorable immune markers cannot be reclassified as a demonstrated survival benefit.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Retain events and inclusion criteria from the complete trials. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Continue learning
Explore Module 7 in PEPTIDE Academy for the full evidence discussion.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-9. DOI: 10.1073/pnas.74.2.725. PMID: 265536.DOI 10.1073/pnas.74.2.725 · PMID 265536
- Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. DOI: 10.1136/bmj-2024-082583. PMID: 39814420.DOI 10.1136/bmj-2024-082583 · PMID 39814420
- Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-7. DOI: 10.1002/hep.510270527. PMID: 9581695.DOI 10.1002/hep.510270527 · PMID 9581695
- Correction: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;389:r1098. DOI: 10.1136/bmj.r1098. PMID: 40447307.DOI 10.1136/bmj.r1098 · PMID 40447307
Related resources
Molecule profile · Module 7
KPV
KPV denotes lysine-proline-valine, a tripeptide related to the terminal sequence of alpha-melanocyte-stimulating hormone. The course discusses peptide transport through PepT1 and inflammatory responses in cell and mouse models. These studies address experimental transport and inflammation, not an established treatment schedule for human intestinal disease.
Molecule profile · Module 7
LL-37
LL-37 is a human cathelicidin peptide with antimicrobial and immunological roles. Its activity depends on tissue, concentration, and biological context; antimicrobial activity is not a blanket clinical benefit. The human wound studies discussed in the course used topical preparations for venous ulcers, a different intervention from an unspecified systemic preparation.
Molecule profile · Module 3
AOD-9604
AOD-9604 is a modified fragment related to the C-terminal region of growth hormone. The rationale discussed in the course concerns metabolic effects attributed to the fragment, rather than assuming that it reproduces every action of full-length growth hormone. Identity, formulation, and route must be specified when comparing reports.